117 related articles for article (PubMed ID: 34019245)
1. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract][Full Text] [Related]
3. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
Li LY; Wang H; Chen X; Li WQ; Cui JW
Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
Jiang Y; Zhao M; Xi J; Li J; Tang W; Zheng X
Front Public Health; 2023; 11():1282374. PubMed ID: 37841712
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Phua LC; Lee SC; Ng K; Abdul Aziz MI
BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Grande E; Bamias A; Galsky MD; Kikuchi E; Davis ID; Arranz JÁ; Rezazadeh Kalebasty A; Garcia Del Muro X; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Puente J; Li JR; Bernhard S; Nicholas A; Telliez J; De Santis M
Eur Urol Open Sci; 2023 Dec; 58():28-36. PubMed ID: 37954037
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract][Full Text] [Related]
9. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
[TBL] [Abstract][Full Text] [Related]
10. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
[TBL] [Abstract][Full Text] [Related]
11. A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.
Parmar A; Richardson M; Coyte PC; Cheng S; Sander B; Chan KKW
Curr Oncol; 2020 Aug; 27(4):e386-e394. PubMed ID: 32905260
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
[TBL] [Abstract][Full Text] [Related]
13. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis.
Zhu Y; Liu K; Qin Q; Zhu H
Front Immunol; 2022; 13():1044678. PubMed ID: 36685541
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France.
Porte F; Granghaud A; Chang J; Kearney M; Morel A; Plessala I; Cawston H; Roiz J; Xiao Y; Solbes MN; Lambert P; Ravaud A; Loriot Y; Thiery-Vuillemin A; Lévy P
PLoS One; 2024; 19(5):e0302548. PubMed ID: 38728337
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.
Zheng Z; Fang L; Cai H
BMJ Open; 2023 Dec; 13(12):e076383. PubMed ID: 38101853
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.
Huo G; Song Y; Chen P
J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606824
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.
Li LF; Qi R; Wei TT; Feng L; Zhang X; Liu Q
Risk Manag Healthc Policy; 2024; 17():927-933. PubMed ID: 38628395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
